In the face of stiff competition, global bio-pharmaceutical companies are on the lookout for profitable investments in different therapeutic areas. One particular area of potential investment is cancer treatment using a class of promising drugs – the Programmed Cell Death Protein 1 (PD-1) Inhibitors. To identify investment opportunities in this therapeutic area, pharmaceutical companies require an in-depth analysis of cancer treatment using PD-1 inhibitors, and a timely review of the competitive landscape.
Against this industry backdrop, WNS — a market leader in offering competitive intelligence and analytics for the pharmaceutical industry — leveraged its vast resources of professionals such as chemists, pharmacists, doctors, pharma marketers and analysts, to conduct an in-depth, research-based, therapy area analysis for cancer treatment using PD-1 inhibitors.
This comprehensive analysis comprises:
Disease pathophysiology (Functional changes associated with the type of cancer)
Disease etiology (Causes and origin of the type of cancer)
Use of PD-1 inhibitors in cancer development and progress
Identification of the available treatment options for the disease
Pipeline analysis to identify the drugs that make up the competitive landscape
The analysis is supplemented with pipeline analysis, which helps identify drugs that constitute the competitive landscape.
WNS' therapy area analysis provides pharmaceutical companies critical insights such as:
Treatment gaps in cancer treatment using PD-1 inhibitors
PD-1 inhibitor molecules that are available as potential investment opportunities
Get more information about WNS’ Pharmaceutical Healthcare Outsourcing Solutions or contact us with questions.
Join the conversation
Research and Analytics
03 October 2021
16 October 2019
16 November 2022